All Articles

As autonomous AI enters healthcare, Datavant joins a key consortium to build the safety guardrails, ensuring patient trust and data integrity remain paramount.

Amid global uncertainty, Deerpath Capital's $452M CLO reset offers a masterclass in financial strategy, prioritizing stability for long-term investors.

With a potential $4 billion on the line, CytomX and Regeneron are building a new class of cancer therapies designed to act like autonomous agents in the body.

A new AI agent from AlphaSense promises to do more than just find data—it executes complex tasks. We look at the tech, trust, and future of work.

As its CEO takes the stage at a key defense summit, a look at how Palladyne AI's pivot from hardware to 'embodied AI' and vertical integration is creating a new model for a defense tech prime.

Vanessa Fusco’s win is more than an award. It’s a strategic play by an industry titan, revealing how social impact is becoming a currency of growth.

A Maine edibles brand is launching nationwide, but the real story is its strategic navigation of legal gray areas and its debut at the Food & Wine Classic.

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

With its massive Resulticks acquisition delayed again, London's Diginex tests investor faith, betting its future on an audacious ethics-meets-commerce vision.

Soccer icon Dwayne De Rosario partners with tech platform LINKSPORTS, aiming to dismantle the financial barriers that sideline one in three Canadian kids.

Nirrin Technologies launches TALOS™, a system using novel laser spectroscopy to eliminate dilution and variability, promising a new standard for biomanufacturing.

Vanessa Fusco's win as top female roofer isn't just a personal victory. It signals a major shift in a male-dominated industry and a new model for social impact.

The new INYY ETF promises massive income from Intel's volatility. But a look under the hood reveals NAV erosion, capped gains, and a return of your own capital.

Crescent's largest-ever fund close highlights booming investor appetite for private credit and promises a major capital infusion for the U.S. lower middle market.

A new AI can detect Parkinson's progression where the current gold standard fails. In a stunning validation, the study was led by the very scientists who created the old method.

Cemvita's breakthrough 75,000-liter scale-up turns biodiesel waste into renewable oil, paving the way for a new generation of Sustainable Aviation Fuel.

The AI boom is hitting a thermal wall. A new solution, born from electric supercar tech, promises to slash energy use and unlock unprecedented power.

TPH Academy's new Chief Growth Officer isn't just a new hire; he's a signal of intent. Steve Sanders brings a playbook for scaling that could reshape the market.

LA's cultural phenomenon Happy Ice expands to Downtown Disney, debuting an all-natural menu and innovative desserts. Founder Lemeir Mitchell's journey comes full circle.

As Prime Medicine prepares for a key investor conference, its next-gen 'search and replace' gene editing technology faces a crucial test. Can it deliver on its promise?